ldhba Antibody

What is LDHA and why is it important in cancer research?

Lactate dehydrogenase A (LDHA) is an enzyme that catalyzes the interconversion of pyruvate and lactate with concomitant interconversion of NADH and NAD+. It plays a critical role in energy metabolism, especially under hypoxic conditions. LDHA is highly expressed in various tumors where it promotes cell proliferation and metastasis through the Warburg effect - the phenomenon where cancer cells produce abundant lactic acid even under normoxic conditions . The enzyme is crucial for tumor glycolysis, making it an important target for cancer research. Studies have shown that LDHA inhibition can reduce glucose consumption by tumor cells and may enhance antitumor immunity by rebalancing glucose availability for T cells within the tumor microenvironment .

What are the structural and molecular characteristics of LDHA?

LDHA is a cytoplasmic enzyme with the following characteristics:

• Molecular weight: Approximately 36.7-37 kDa

• Structure: Forms tetramers consisting of four subunits of LDHA and/or LDHB, differently assorted depending on tissue type

• Gene location: The human LDHA gene is located on chromosome 11

• Alternative names: LDH1, GSD11, HEL-S-133P, LDHM, PIG19, L-lactate dehydrogenase A chain, LDH muscle subunit

LDHA has a higher affinity for pyruvate and favors the conversion of pyruvate to lactate, which sustains glycolysis, while LDHB preferentially converts lactate to pyruvate .

What are the typical applications for LDHA antibodies in research?

LDHA antibodies are used in multiple experimental applications:

The optimal dilution should be determined experimentally for each specific antibody and application .

How should I optimize LDHA antibody concentration for Western blotting?

For optimal Western blot results with LDHA antibodies:

• Initial titration: Start with manufacturer's recommended dilution (typically 1:1000) and test a range (e.g., 1:500, 1:1000, 1:5000) to determine optimal signal-to-noise ratio.

• Sample preparation: For LDHA detection, use RIPA buffer containing PMSF for protein extraction. Load 20-30 μg protein per lane .

• Positive controls: Use cell lines known to express LDHA such as HEK-293, MCF-7, HepG2, Daudi, or MOLT-4 cells .

• Detection optimization: LDHA typically appears as a band at 32-37 kDa. Use chemiluminescence detection for best results .

• Validation: Compare results with published literature showing expected band sizes. Multiple bands may indicate isoforms, degradation products, or post-translational modifications .

Remember that LDHA antibody performance can vary between manufacturers and even between lots, so validation with known positive samples is crucial .

What factors should be considered when selecting between monoclonal and polyclonal LDHA antibodies?

When choosing between monoclonal and polyclonal LDHA antibodies, consider these research-specific factors:

For studies involving specific LDHA variants or post-translational modifications, understanding the antibody's epitope is crucial. For instance, LDHA can undergo acetylation at A2 and K5, and phosphorylation at T3, which might affect antibody recognition depending on the epitope location .

How can I validate the specificity of an LDHA antibody?

Thorough validation of LDHA antibody specificity should include:

• Positive and negative controls:

  • Positive: Cell lines with known LDHA expression (HEK-293, MCF-7, HepG2)

  • Negative: LDHA-knockout or LDHA-silenced cells using shRNA/siRNA

• Multiple detection methods: Confirm results using at least two techniques (e.g., WB and IHC or IF)

• Peptide competition: Pre-incubate antibody with immunizing peptide to block specific binding

• Band size verification: Confirm molecular weight matches predicted size (32-37 kDa for LDHA)

• Cross-reactivity assessment: Test reactivity against related proteins (especially LDHB) if studying specific isoforms

• Literature comparison: Compare your results with published data using the same antibody

• Gene silencing verification: Use shRNA to knock down LDHA and confirm decreased antibody signal, as demonstrated in studies using MISSION® shRNA lentivirus in MDA-MB-231 cells

Proper validation ensures experimental results are reliable and reproducible across different studies.

How does LDHA expression pattern differ across tumor types?

LDHA expression shows characteristic patterns across different cancer types, which has important implications for research:

• Expression levels: Studies show varied LDHA overexpression across cancer types:

  • Particularly high in breast cancer (especially triple-negative breast cancer)

  • Elevated in melanoma and colon cancer models where LDHA inhibition enhances immunotherapy response

  • Present in lung cancers, as evidenced by positive IHC detection in lung tissues

  • Detectable in thyroid cancer tissue through IHC analysis

• Prognostic value: LDHA expression levels correlate with aggressive phenotypes and poorer prognosis in multiple cancer types, making it a valuable research target for understanding cancer progression.

• Association with other markers: TCGA data analysis shows an inverse relationship between glycolysis genes (including LDHA) and genes related to immune cell activation in melanoma specimens, suggesting tumor glycolysis may negatively condition the tumor immune microenvironment .

• Functional significance: LDHA expression supports the Warburg effect, where cancer cells rely on aerobic glycolysis even in the presence of oxygen, producing lactic acid that creates an acidic microenvironment conducive to invasion and metastasis .

These expression patterns make LDHA an important marker in cancer research and potentially valuable therapeutic target.

What methodological approaches are effective for studying LDHA's role in tumor metabolism?

To effectively investigate LDHA's role in tumor metabolism, researchers should consider these methodological approaches:

Each of these approaches provides complementary insights into LDHA's multifaceted role in tumor metabolism and immune evasion.

Why might LDHA silencing alone show limited effects in some cancer cell lines?

The observation that LDHA silencing alone doesn't always affect cell viability or metabolism requires nuanced analysis:

• Compensatory mechanisms: Research with MDA-MB-231 breast cancer cells showed that despite effective LDHA knockdown (to less than 1% of control levels), there were no changes in cell viability, lactic acid production, ATP generation, glucose consumption, or basic metabolic rate . This suggests robust compensatory mechanisms.

• LDH isoform redundancy: Whole-transcriptome analysis of MDA-MB-231 cells revealed the following LDH isoform distribution:

  • LDHA: 30.47%

  • LDHB: 69.36%

  • LDHC: 0.12%

  • LDHD: 0.05%

  The predominance of LDHB (69.36%) explains why LDHA silencing alone might be insufficient in some cell lines.

• Context-dependent function: The effect of LDHA inhibition may depend on:

  • The tumor microenvironment (oxygen availability, nutrient accessibility)

  • Genetic background of the cell line

  • Metabolic flexibility of specific cancer types

  • Expression of alternative metabolic enzymes

• Research implications: These findings highlight the importance of:

  • Characterizing the full LDH isoform profile before targeting LDHA

  • Considering combined targeting approaches (e.g., LDHA+LDHB)

  • Understanding the complex metabolic networks in cancer cells

  • Evaluating the tumor microenvironment when interpreting LDHA inhibition results

This complexity underscores why careful experimental design and comprehensive metabolic profiling are essential when studying LDHA function in cancer.

How can researchers distinguish between LDHA and LDHB in experimental systems?

Distinguishing between LDHA and LDHB is crucial for accurate research outcomes, particularly in systems where both isoforms are present:

• Antibody selection:

  • Use isoform-specific antibodies validated for cross-reactivity testing

  • Confirm specificity by testing on recombinant LDHA and LDHB proteins

  • Select antibodies targeting regions with low sequence homology between isoforms

• Molecular techniques:

  • RT-qPCR: Design primers specific to unique regions of LDHA and LDHB transcripts

  • Isoform-specific siRNA/shRNA: Validate knockdown specificity using both transcript and protein level measurements

  • Transcriptome analysis: Quantify relative expression as demonstrated in MDA-MB-231 cells (30.47% LDHA vs. 69.36% LDHB)

• Functional assays:

  • Enzymatic activity direction: LDHA preferentially converts pyruvate to lactate, while LDHB favors lactate to pyruvate conversion

  • Inhibitor specificity: Some small molecule inhibitors show preference for LDHA over LDHB

• Subcellular localization:

  • Immunofluorescence with isoform-specific antibodies can reveal different distribution patterns

  • Cell fractionation followed by Western blot analysis

• Mass spectrometry:

  • Targeted proteomics approaches can distinguish and quantify LDHA and LDHB based on unique peptide sequences

Understanding the specific roles of each isoform is essential for interpreting experimental results, especially given their different catalytic preferences and tissue distribution patterns.

What are the optimal strategies for quantifying LDHA in complex biological samples?

For accurate quantification of LDHA in complex biological samples, researchers should consider these strategic approaches:

• Protein quantification techniques:

  • Western blot (semi-quantitative): Use recombinant LDHA protein standards for calibration curves; analyze band intensity with software like Image J for average gray value analysis

  • ELISA: Commercial antibody pairs provide quantitative measurement with ranges of 39.06-5000 pg/mL

  • Mass spectrometry: Targeted approaches using unique LDHA peptides provide absolute quantification

• Sample preparation optimization:

  • For tissue samples: 20 mg of specimen lysed with RIPA buffer containing PMSF

  • For cells: Standard lysis protocols with protease inhibitors

  • Protein concentration determination using BCA protein assay kit

• Internal controls and normalization:

  • Use housekeeping proteins (β-actin) for normalization

  • Include positive control samples with known LDHA expression (HEK-293, HepG2, MCF-7)

  • Run multiple technical replicates to assess measurement variability

• Accounting for post-translational modifications:

  • Consider phosphorylation at T3 and acetylation at A2 and K5

  • Use antibodies that detect total LDHA regardless of modification state

  • For modification-specific research, use antibodies targeting specific modified epitopes

• Enzymatic activity correlation:

  • Complement protein quantification with enzymatic activity assays

  • Understand that protein levels may not directly correlate with enzymatic activity due to post-translational regulation

These approaches ensure reliable quantification across different experimental contexts and sample types.

How should researchers approach epitope mapping for LDHA antibodies in their experimental design?

Understanding antibody epitopes is critical for experimental design and interpretation. For LDHA antibodies:

• Significance of epitope knowledge:

  • Helps predict potential cross-reactivity with related proteins

  • Informs whether post-translational modifications might affect antibody binding

  • Guides selection for specific applications (e.g., native vs. denatured conditions)

  • Enables more informed troubleshooting when unexpected results occur

• Practical approaches to epitope mapping:

  • Manufacturer information: Review the immunogen sequence information provided (e.g., "LDHA fusion protein Ag16703" or "Recombinant Fragment Protein within Human LDHA aa 100 to C-terminus")

  • Peptide arrays: Test antibody binding against overlapping peptides spanning LDHA sequence

  • Truncation mutants: Express fragments of LDHA to narrow down binding region

  • Competitive binding assays: Use known epitope antibodies to test competition

• Application-specific considerations:

  • For Western blotting: Epitopes in denaturation-resistant regions are preferred

  • For immunoprecipitation: Epitopes exposed on the protein surface in native conformation

  • For immunohistochemistry: Epitopes that withstand fixation and antigen retrieval

• Experimental validation:

  • Test antibody against LDHA mutants lacking potential epitope regions

  • Confirm binding is lost when critical amino acids are altered

  • Evaluate binding under various denaturing conditions

Understanding the specific epitope recognized by an LDHA antibody provides crucial context for experimental design and helps explain unexpected results that might arise from epitope masking or modification in different experimental conditions.

How are computational approaches being integrated into antibody-based LDHA research?

Computational methods are transforming antibody-based LDHA research in several key ways:

• Generative models for antibody design:

  • Recent benchmarking studies have evaluated various generative models, including LLM-style, diffusion-based, and graph-based models

  • Log-likelihood scores from these models correlate with experimentally measured binding affinities, positioning them as reliable metrics for ranking antibody sequence designs

  • Diffusion-based models trained on large, diverse synthetic datasets show enhanced ability to predict and score binding affinities

• Structural prediction integration:

  • For models requiring structural inputs, tools like ImmuneBuilder2 and IgFold are being used to predict antibody structures

  • Structure guidance approaches are being developed where only the sequence is masked, and structure is used to guide sampling

• Quantitative structure-function relationship models:

  • Computational models can now predict how specific LDHA epitopes interact with antibodies

  • These models help design antibodies targeting specific functional domains of LDHA

• Performance metrics:

  • Spearman correlation values (e.g., 0.37 for Nature HER2 data) quantify how well computational predictions align with experimental measurements

  • Two evaluation modes are commonly used: De Novo (DN) where both sequence and structure are masked, and Structure Guidance (SG) where only sequence is masked

These computational approaches can significantly accelerate antibody development while reducing experimental costs, ultimately enhancing LDHA-targeted research capabilities.

What is the significance of LDHA in immunotherapy research?

LDHA has emerged as a critical factor in immunotherapy research due to its impact on the tumor microenvironment:

These findings establish LDHA as both a biomarker and therapeutic target in the rapidly evolving field of cancer immunotherapy.

How do post-translational modifications of LDHA affect antibody recognition and function?

Post-translational modifications (PTMs) of LDHA present both challenges and opportunities for researchers:

• Key LDHA post-translational modifications:

  • Acetylation at positions A2 and K5

  • Phosphorylation at position T3

  • These modifications can regulate LDHA activity, stability, and interactions

• Impact on antibody recognition:

  • PTMs can alter epitope structure or accessibility

  • Antibodies raised against unmodified peptides may fail to recognize modified LDHA

  • Modification-sensitive antibodies may show inconsistent results depending on the cellular context and metabolic state

• Research strategies for PTM-aware antibody selection:

  • Use antibodies validated for total LDHA detection regardless of modification state

  • For PTM studies, employ modification-specific antibodies that selectively recognize acetylated or phosphorylated forms

  • Validate results with multiple antibodies recognizing different epitopes

  • Consider using mass spectrometry to confirm PTM status in parallel with antibody-based detection

• Functional significance:

  • PTMs can alter LDHA enzymatic activity without changing protein levels

  • Understanding the relationship between specific PTMs and LDHA function requires careful selection of antibodies that either recognize or are insensitive to these modifications

  • PTM patterns may vary between normal and cancer cells, offering potential diagnostic or therapeutic opportunities

This nuanced understanding of LDHA PTMs is essential for accurate interpretation of experimental results and may reveal new regulatory mechanisms governing cancer metabolism.

Why might Western blot results for LDHA show unexpected bands or patterns?

When LDHA Western blots show unexpected results, systematic troubleshooting is essential:

• Multiple bands: Several legitimate explanations exist for observing multiple bands:

  • Isoforms: LDHA can exist in different splice variants

  • Post-translational modifications: Phosphorylation or acetylation can alter migration

  • Degradation products: Partial proteolysis during sample preparation

  • Cross-reactivity: Antibody recognition of related LDH family members (particularly LDHB)

• Unexpected molecular weight:

  • Expected LDHA size is 32-37 kDa

  • Higher MW bands may indicate post-translational modifications or incomplete denaturation

  • Lower MW bands often suggest proteolytic degradation

  • Verify with purified recombinant LDHA protein as positive control

• Methodological solutions:

  • Sample preparation optimization:

    • Add fresh protease inhibitors to lysis buffer

    • Maintain samples at 4°C during processing

    • Use RIPA buffer containing PMSF for extraction

  • Antibody validation:

    • Test multiple antibodies targeting different epitopes

    • Check if unexpected bands disappear with peptide competition

    • Verify specificity using LDHA knockdown or knockout samples

  • Technical adjustments:

    • Optimize protein loading (20-30 μg/lane)

    • Adjust antibody dilution (test range: 1:500-1:5000)

    • Try different blocking agents to reduce non-specific binding

• Verification strategies:

  • Run samples alongside cell lines with known LDHA expression (HEK-293, MCF-7, HepG2, etc.)

  • Consider using Simple Western technology for increased specificity

  • Complement with immunoprecipitation followed by Western blot

Understanding these factors ensures more accurate interpretation of Western blot results.

What approaches can resolve inconsistent immunohistochemistry staining with LDHA antibodies?

Resolving inconsistent IHC staining for LDHA requires systematic optimization:

• Antigen retrieval optimization:

  • Test multiple methods:

    • Heat-mediated retrieval in TE buffer pH 9.0 (recommended for some LDHA antibodies)

    • Alternative retrieval with citrate buffer pH 6.0

  • Optimize retrieval duration and temperature

  • Compare pressure cooker vs. water bath methods

• Antibody titration and validation:

  • Test dilution series (recommended range: 1:20-1:200)

  • Verify specificity with positive controls (human skeletal muscle tissue shows reliable LDHA expression)

  • Include isotype control antibodies to assess non-specific binding

  • Consider using monoclonal antibodies for more consistent results (e.g., Cell Signaling's C4B5 clone)

• Detection system optimization:

  • Compare different visualization methods (DAB vs. fluorescent detection)

  • Test amplification systems for weak signals

  • Optimize incubation times and temperatures

  • Consider automated staining platforms for improved reproducibility

• Tissue-specific considerations:

  • Optimize fixation time (overfixation can mask epitopes)

  • Use freshly cut sections (antigen deterioration occurs in stored sections)

  • Compare different fixatives if possible

  • Account for endogenous peroxidase activity with appropriate blocking

• Troubleshooting specific issues:

  • High background: Increase blocking duration, optimize antibody dilution

  • Weak signal: Extend primary antibody incubation, enhance antigen retrieval

  • Variable staining: Standardize all protocol steps, use positive control on each slide

  • Edge artifacts: Ensure adequate section hydration, apply hydrophobic barrier

These approaches should systematically resolve most IHC inconsistencies when working with LDHA antibodies.

How can researchers address LDHA antibody batch variability in long-term studies?

Managing antibody batch variability is crucial for longitudinal studies involving LDHA:

• Proactive batch management strategies:

  • Purchase larger lots of antibody at study initiation

  • Aliquot antibodies to minimize freeze-thaw cycles

  • Store according to manufacturer recommendations (typically -20°C with 50% glycerol)

  • Document lot numbers and maintain detailed inventory

• Comprehensive batch validation protocol:

  • Cross-validation assay: Test new batch alongside current batch

  • Standard curve comparison: Generate quantitative data for comparison

  • Multiple application testing: Verify performance across all planned applications

  • Sensitivity assessment: Determine detection limits of each batch

• Reference standards implementation:

  • Create internal reference standards:

    • Cell lysates with stable LDHA expression

    • Recombinant LDHA protein standards

    • Tissue microarrays for IHC applications

  • Include these standards in each experiment

• Normalization approaches:

  • Use normalization factors derived from standard sample results

  • Apply statistical correction based on batch performance metrics

  • Consider using recombinant antibodies for improved consistency (e.g., "Rabbit Anti-LDHA Recombinant Antibody (VS3-CJ201)")

• Data integration strategies:

  • Apply batch correction algorithms in data analysis

  • Document batch transitions in research records

  • Consider temporal separation in data presentation/analysis

  • Validate key findings across multiple batches